Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma.

Trial Profile

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Rituximab (Primary) ; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Fludarabine; Interferon; Methylprednisolone; Mitoxantrone; Prednisone; Procarbazine; Vincristine
  • Indications B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Sep 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 08 Sep 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top